nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial-Reference-Cited by-同舟云学术

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

Published:2015-01-31 Issue:2 Volume:107 Page:dju413-dju413
ISSN:0027-8874
Container-title:JNCI Journal of the National Cancer Institute
language:en
Short-container-title:JNCI Journal of the National Cancer Institute

Author:

Goldstein D.,El-Maraghi R. H.,Hammel P.,Heinemann V.,Kunzmann V.,Sastre J.,Scheithauer W.,Siena S.,Tabernero J.,Teixeira L.,Tortora G.,Van Laethem J.-L.,Young R.,Penenberg D. N.,Lu B.,Romano A.,Von Hoff D. D.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/107/2/dju413/17314123/dju413.pdf

Reference32 articles.

1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

2. Pancreatic adenocarcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

4. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

5. Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study

Cited by 505 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial;The Lancet Gastroenterology & Hepatology;2024-10

2. Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer;International Immunopharmacology;2024-09

3. NALIRIFOX en première ligne de traitement de l’adénocarcinome pancréatique métastatique;Bulletin du Cancer;2024-09

4. Outcomes After Multimodality Treatment of Pancreatic Cancer in an Unselected Single-Center Cohort;Cancer Management and Research;2024-08

5. XRCC2 knockdown effectively sensitizes esophageal cancer to albumin-paclitaxel in vitro and in vivo;Biochemical Genetics;2024-07-24